Position in XFOR
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$356,386
+$104,211 QoQ
Shares Held
76,314
-42.5% QoQ
Ownership
0.077%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#38
of 89 holders
Holding Since
Sep 2023
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in XFOR Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $104,909,103 across 164 Biotechnology names. XFOR ranks #96 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IOVA |
Iovance Biotherapeutics, Inc.
|
655,318 | $2,726,122 | |
| 2 | IMVT |
Immunovant, Inc.
|
65,267 | $2,514,737 | |
| 3 | GOSS |
Gossamer Bio, Inc.
|
187,337 | $2,472,846 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
9,419 | $2,305,488 | |
| 5 | CABA |
Cabaletta Bio, Inc.
|
668,563 | $2,079,230 | |
| 6 | MLTX |
MoonLake Immunotherapeutics
|
106,695 | $2,077,351 | |
| 7 | ATYR |
aTYR PHARMA INC
|
3,454,863 | $2,062,553 | |
| 8 | CORT |
Corcept Therapeutics Inc
|
23,257 | $2,022,196 |
All Filings in XFOR
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $356,386 | 76,314 | Shares | Sole | 2026-08-06 | |
| 2025-06-30 | $252,175 | 132,724 | Shares | Sole | 2025-07-22 | |
| 2024-12-31 | $934,848 | 1,273,635 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $339,647 | 507,694 | Shares | Sole | 2024-11-05 | |
| 2024-03-31 | $446,219 | 321,021 | Shares | Sole | 2024-05-03 | |
| 2023-12-31 | $792,998 | 945,171 | Shares | Sole | 2024-02-16 | |
| 2023-09-30 | $677,529 | 621,587 | Shares | Sole | 2023-11-15 | |
| No filing history on record for this holder in this stock. | ||||||